Results 221 to 230 of about 86,631 (266)
Some of the next articles are maybe not open access.
2011
Angiotensin receptor blockers (ARBs) were developed to providean alternative approach to interrupting the renin–angiotensin system(RAS), which was pharmacologically distinct from that ofangiotensin converting enzyme (ACE) inhibitors. By selectivelyblocking the angiotensin II type 1 (AT1) receptor, ARBs werethought to offer the potential for more ...
openaire +1 more source
Angiotensin receptor blockers (ARBs) were developed to providean alternative approach to interrupting the renin–angiotensin system(RAS), which was pharmacologically distinct from that ofangiotensin converting enzyme (ACE) inhibitors. By selectivelyblocking the angiotensin II type 1 (AT1) receptor, ARBs werethought to offer the potential for more ...
openaire +1 more source
Vascular benefits of angiotensin receptor blockers
Expert Opinion on Investigational Drugs, 2007There is convincing evidence that angiotensin II, through activation of the angiotensin II type 1 (AT1) receptor, is involved in the atherosclerotic process. Similarly, angiotensin receptor blockers decrease vascular inflammation, hypertrophy and thrombosis, which are the key components of the progression of atherosclerosis.
openaire +2 more sources
Reduction of proteinuria with angiotensin receptor blockers
Nature Clinical Practice Cardiovascular Medicine, 2008Renal pathophysiology is elicited by activation of angiotensin II type 1 (AT(1)) receptors at all stages of renovascular disease. Angiotensin receptor blockers (ARBs) that specifically block the AT(1) receptor offer the potential to prevent or delay progression to end-stage renal disease independently of reductions in blood pressure.
openaire +2 more sources
Angiotensin receptor blockers and angiotensin receptor–neprilysin inhibitors
2022Abstract This chapter addresses angiotensin receptor blockers (ARBs) and angiotensin receptor–neprilysin inhibitors (ARNIs). ARBs or angiotensin II receptor antagonists were introduced as a potentially superior alternative to an angiotensin converting enzyme (ACE) inhibitor and, later, as a possible addition to an ACE inhibitor.
openaire +1 more source
Are angiotensin receptor blockers neuroprotective?
Current Hypertension Reports, 2004Stroke is one of the leading causes of invalidism and death in the industrialized world. Among others, the renin- angiotensin system (RAS) has been implicated in the pathogenesis and outcome of ischemic events, including stroke. Angiotensin II (Ang II), the major effector peptide of the RAS, exerts most of its well-defined physiologic and ...
Christa, Thöne-Reineke +6 more
openaire +2 more sources
Angiotensin-II Receptor Blockers
2000As described in the previous chapter, the renin-angiotensin system (RAS) plays an important role in the body’s regulation of arterial blood pressure. The effector hormone of the RAS is angiotensin II, which maintains the systemic vascular resistance and extracellular fluid volume through its direct and indirect vasoconstrictive and blood volume ...
William H. Frishman +2 more
openaire +1 more source
Angiotensin II receptor blockers
Coronary Artery Disease, 1999H, Thai, T, Raya
openaire +2 more sources
Angiotensin II Receptor Blockers
2014The angiotensin II receptor blockers (ARBs) inhibit the activity of angiotensin II at the angiotensin II receptor level (AT-1, AT-2 receptors). Losartan potassium is the prototype of the ARBs. Others are candesartan, irbesartan, valsartan, telmisartan, olmesartan, eprosartan, and azilsartan.
Esen Özkaya +1 more
openaire +1 more source
Pharmacology of angiotensin receptors and AT 1 receptor blockers
Basic Research in Cardiology, 1998O, Chung, T, Unger
openaire +2 more sources
Angiotensin Receptor Blockers and Parkinson Disease
The American Journal of Medicine, 2023Noriaki Kou +4 more
openaire +2 more sources